Network & Support

Support our fight against COVID-19

The FLCCC needs your support to continue and expand its efforts to share the latest information on effective treatments of COVID-19 patients while the vaccine is being distributed.

Your donations will help support the FLCCC Alliance with the rising costs of public relations, research, medical education, translation, advocacy, and lobbying.

Postal contributions: FLCCC Alliance, 2001 L St NW Suite 500, Washington, DC 20036

Thank you for your help! And to all of our thoughtful contributors, we want you to know how grateful we are to you for recognizing and so generously supporting the urgency and importance of our work. We wish you a lifetime of good health.

Carry Our Message with the Fun Items in our FLCCC Support Store

 Visit the new FLCCC Support Store

We are excited to announce that we have opened an online store where you can help to support our lifesaving mission just by purchasing our specially branded merchandise.


Our work to save as many lives as we possible can is urgent—both in the United States and across the world. But it requires that we secure enough revenue for the FLCCC—a 501(c)3 charitable organization—to continue implementation and promotion of our bold, global initiatives. All funds received through purchases will go directly towards fulfillment of our resolve to end this pandemic and save every life we can. Thank you!

About us

The Front Line Covid-19 Critical Care Alliance (FLCCC Alliance) is a 501c3 non-profit organization* founded in March 2020 with the simple goal of developing the most effective treatment protocols possible for COVID-19 patients. Our approach is based on the use of outcome-based medicine by repurposing existing drugs to minimize fatalities and reduce long-term effects in patients suffering from this pandemic.

Our founding members are highly published critical care specialists from major academic medical centers with nearly 2,000 medical publications and numerous major contributions to the field of medicine.

As the pandemic takes its toll on countries and economies worldwide, most governments have focused on vaccine development and vaccine distribution to beat COVID-19.

The situation

Thousands of people are suffering and dying while the vaccine is being produced and distributed. It will take months before we reach herd immunity through the vaccine and extended lockdowns may cause immeasurable long-term harm to our economies.

The solution

The FLCCC has identified 2 effective therapy protocols that can help slow down the pandemic to alleviate the current burden on our healthcare system and save lives at the same time:

  1. MATH+ — a combination therapy intended for the hospitalized patient and consisted of the core therapies of methylprednisolone, ascorbic acid, thiamine, and heparin, all delivered intravenously along with multiple adjunctive medicines
  2. I-MASK+ — a prophylactic and early treatment protocol centered around the use of ivermectin, a historically important medicine that has already won the Nobel Prize in medicine for its global impact in ridding the world of parasitic diseases and that shows promising anti-viral and anti-inflammatory properties against COVID-19
  3. I-MASS — a protocol created for generalized distribution during mass outbreaks and in low-resource countries. To achieve maximal impact as well as ease of deployment with the lowest burden of required elements, the I-MASS treatment approach is centered on the fewest, core, high impact elements such as the drug Ivermectin.

How else can you support the FLCCC Alliance

  • Download and share our MATH+ and I-MASK+ life-saving protocols to your family, friends and doctors.
  • Write to your elected officials to review our latest analyses, particularly on the repurposing of ivermectin to fight COVID-19.
  • If you, your friend or family has benefited from the MATH+ or I-MASK+ protocols, post a testimonial of your experience on social media or send us an email.
  • If your doctor prescribed you ivermectin or any other effective treatments to help fight COVID-19, contact us and connect us to your doctor so we can further study what works and what doesn’t.

Additional information

March 6, 2021: Ivermectin is either officially used, or tolerated as an off-label medicine against COVID-19 in the following countries: Czech Republic, Slovenia, Macedonia, Bulgaria, Romania, Peru, Argentina, Mexico, Bangladesh, India, Belize, South Africa and Zimbabwe.

January 14, 2021: The NIH allows ivermectin as a COVID-19 treatment!

Our latest meta-analysis of current international studies is showing mounting evidence that ivermectin can be highly effective in reducing transmission, hospitalization, and death in COVID-19:  Review on the Efficacy of Ivermectin in COVID-19, respectively the  One-page summary of the review.

  • Pierre Kory presented the latest data on ivermectin to the NIH COVID-19 Treatment Guideline committee on Jan 6, 2021 (see our  Press Release from Jan 7, 2021), and on Jan. 14, 2021, the NIH removed its recommendation against the use of ivermectin to treat COVID-19, giving ivermectin the same status – neither for nor against its use in COVID treatment – as experimental convalescent plasma and monoclonal antibodies (see our  Press Release from Jan 7, 2021 and our  Answer to the NIH statement from Jan 18, 2021).
  • Andrew Hill, a PhD Senior Visiting Research Fellow in the Department of Pharmacology at the University of Liverpool, is soon to present his own analysis of the effectiveness of ivermectin to the WHO by the end of Jan 2021 as part of his work for Unitaid.

*The FLCCC Alliance has been incorporated in the State of Delaware and received 501(c)3 federal tax-exempt status as a public charity [Status: 170(b)(1)(A)(vi); Employer ID number: 85-2270146]. You can download the Determination Letter (IRS) here.

To learn more about our work, please go to About the FLCCC Alliance, there you will also find our Mission Statement and Objectives.